HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case

Background: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibody (HMGCR antibody) antibody-associated myopathy is a rare disease. HMGCR antibody-associated myopathy in patient with endometrial cancer is extremely rare. Case Report: A 60-year-old woman without statin exposure presented with endometrial cancer Stage IIIC1 (T2N1M0) and HMGCR antibody-associated myopathy. After diagnosis, the patient received chemotherapy combining paclitaxel and carboplatin for endometrial cancer, and steroid and immunoglobulin for HMGCR antibody-associated myopathy. Two months after two cycles of chemotherapy, she died. Autopsy revealed that she died of HMGCR antibody-associated myopathy. Conclusion: In case of myopathy in patients with endometrial cancer, HMGCR antibody-associated myopathy should be considered.

Endometrial cancer; HMGCR antibody-associated myopathy.

[1] Staff A.C., Trovik J., Eriksson A.G.Z., Wik E., Wollert K.C., Kempf T., Salvesen H.B.: “Elevated plasma growth differentiation factor15 correlates with lymph node metastases and poor survival in endometrial cancer.” Clin Cancer Res, 2011, 17, 4825. [2] Mammen A.L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., Casciola-Rosen L.A.: “Auto-antibodies against 3-hydroxy-3-methylglutarylcoenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy.” Arthritis Rheum, 2011, 63, 713.

[3] Mammen A.L., Pak K., Williams E.K., Brisson D., Coresh J., Selvin E., Gaudet D.: “Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.” Arthritis Care Res., 2012, 64, 269.

[4] Mizuma A., Kouchi M., Netsu S., Yutani S., Kitao R., Suzuki S., Murata K., Nagata E., Takizawa S.: “Paraneoplastic anti-3-hydroxy-3- methylglutary-coenzyme A reductase antibody-positive immunemediated necrotizing myopathy in a patient with uterine cancer.” Intern. Med., 2017, 56, 1915.

[5] Tsujikawa K., Hara K., Muro Y., Nakanishi H., Niwa Y., Koike M., et al.: “HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.” Neurology, 2016, 87, 841.

[6] Kadoya M., Hida A., Hashimoto Maeda M., Taira K., Ikenaga C., Uchio N., et al.: “Cancer association as a risk factor for antiHMGCR antibody-positive myopathy.” Neurol. Neuroimmunol. Neuroinflamm., 2016, 3, e290.